Abstract:

Angiogenesis play an important role in the process of cell growth，and it is one of the basic characteristics of malignant tumors. So， antiangiogenesis is an effective way to antitumor. Apatinib is a novel smallmolecule vascular endothelial growth factor receptor2 tyrosine kinase inhibitor. Through specific inhibition of vascular endothelial cells factor-2 tyrosine kinase activity， apatinib plays antiangiogenic and antitumor roles. Apatinib has demonstrated encouraging anticancer activity across a broad range of malignancies， including gastric cancer， breast cancer， non-small cell lung cancer， hepatocarcinoma and soft tissue tumor etc. This paper will make a review of clinical trials of apatinib to some solid tumors and provides reference for clinical practice in therapeutic options for cancer patients.